On the contrary, increased expression of E2 HSD17B-synthetizing enzymes HSD17B1, HSD17B7 and HSD17B5 correlates with better ER+ breast cancer patient outcome for RFS and/or DMFS [26]. This evidence concerns the gene HSD17B1 and breast carcinoma.